NCT03962543 2026-04-08
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07407803 2026-04-06
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT03975829 2026-04-02
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Active not recruiting
NCT06360406 2026-03-31
Real-World Treatment Study of Koselugo (Selumetinib)
AstraZeneca
Recruiting
NCT05028166 2026-03-27
Individual Patient Compassionate Use of Mirdametinib
SpringWorks Therapeutics, Inc.
Available
NCT04924608 2026-03-23
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT06541847 2026-03-20
INSPIRE-NF1
Healx Limited
Phase 2 Recruiting
NCT06175637 2026-02-12
PEDIA
AstraZeneca
Active not recruiting
NCT04590235 2026-01-30
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT06961565 2025-12-04
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Pasithea Therapeutics Corp.
Phase 1 Recruiting
NCT07024394 2025-06-17
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1/2 Not yet recruiting